A+ Stock Grade Summary:
| VALUE: |
|
|
| GROWTH: |
|
|
| MOMENTUM: |
|
|
| EPS REVISIONS: |
|
|
| QUALITY: |
|
|
COMPANY SUMMARY
Revium Rx. operates as a pre-clinical stage biopharmaceutical company focused on the development of nanoparticle-based therapies in the United States. The company develops lipid-based platforms for a variety of uses including antimicrobial resistance and solid tumors; specializes in infectious diseases, including antibiotic-resistant infections, solid tumors, and vaccination; and develops nano-liposomal particles (NLP) based pharmaceutical candidates. It also offers Nano-Mupirocin, a NLP-based formulation of potent antibiotic mupirocin. In addition, the company develops nanoparticles-based formulation of an angiotensin receptor blockers; novel adjunct for cancer therapies: and novel immunization based on liposomal protein-loaded technology. The company was formerly known as Revium Recovery Inc. and changed its name to Revium Rx. in December 2024. Revium Rx. was incorporated in 1997 and is headquartered in Herzliya, Israel.
Financial Summary
| Share Statistics | RVRC | Industry Median |
Percentile (All Stocks) |
|
| Market Cap (Mil) | $86.8 | $289.2 | 20% |
|
| Shares Out (Mil) | 60.7 | 54.1 | 52% |
|
| Institutional Ownership | na | 93.1% | na |
|
| Float (Mil) | na | 42.2 | na |
|
| Beta | -0.76 | 0.94 | 1% |
|
| Avg Daily Volume (000s) | 0 | 451 | 0% |
|
| Price Change (52-week) |
(28.5%) | 59.8% | 25% |
|
| Growth | RVRC | Industry Median |
Percentile (All Stocks) |
|
| Sales (5yr) | na | 14.1% | na |
|
| Net Income (5yr) | na | (10.1%) | na |
|
| EPS (5yr) | na | 15.9% | na |
|
| Dividends (5yr) | na | 0.0% | na |
|
| Cash Flow (5yr) | na | (15.6%) | na |
|
| Estimates | Qtrly | Current Fiscal Year |
Next Fiscal Year |
|
| # of Estimates | na | na | na | |
| Current EPS | na | na | na | |
| Month Ago EPS | na | na | na | |
| # Rev Up | na | na | na | |
| # Rev Down | na | na | na | |
| Three Months Ago EPS | na | na | na | |
| Year/Year Chg | na | na | na | |
| Financials | RVRC | Industry Median |
Percentile (All Stocks) |
|
| Sales (TTM) (Mil) | na | $37 | na |
|
| Net Income (TTM) (Mil) | ($13) | ($43) | 27% |
|
| EPS (TTM) | ($0.218) | ($1.500) | 33% |
|
| Operating Cash Flow (TTM) (Mil) | ($3) | ($31) | 28% |
|
| Net Cash Flow (TTM) (Mil) | na | $2 | na |
|
| Long-Term Debt (Q1) (Mil) | $0 | $4 | 0% |
|
| Enterprise Value (Q1) (Mil) | $86 | $190 | 20% |
|
| Valuation | RVRC | Industry Median |
Percentile (All Stocks) |
|
| P/B | 15.89 | 2.84 | 94% |
|
| P/E | na | 20.4 | na |
|
| Dividend Yield | na | 0.0% | na |
|
| PEG (5yr hist) | na | 1.1 | na |
|
| Ratios | RVRC | Industry Median |
Percentile (All Stocks) |
|
| Gross Margin | na | 66.9% | na |
|
| Net Margin | na | (74.2%) | na |
|
| ROA | (100.6%) | (47.8%) | 6% |
|
| ROE | (109.9%) | (55.0%) | 8% |
|
| Liabilities to Assets | 22.4% | 29.7% | 15% |
|
| F-Score | 2 | 3 | 7% |
|
Revium Rx. did not pass any screens on 9/3/2026.
